Abstract
Diabetic cardiomyopathy (DCM) is a prevalent complication in diabetic patients, and its pathogenic mechanism involves multiple endocrine and metabolic factors, with dyslipidemia playing a pivotal role in the pathogenesis of the disease. Recent studies have highlighted the importance of peptides in energy metabolism and their potential effect on the onset and development of DCM by affecting the function of perivascular adipose tissue (PVAT). The present review aims to examine the effect of these peptides on perivascular adipose tissue and myocardial metabolism during the pathogenesis of DCM, focusing on the role of peptides distributed in perivascular adipose tissue in cardioprotection and their underlying mechanisms of action. In addition, we will explore future research directions and potential clinical applications of these peptides in the treatment of DCM.